Vanguard Group
URGN icon

Vanguard Group’s UroGen Pharma URGN Stock Holding History

Vanguard Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.3M Buy
439,751
+135,966
+45% +$2.95M ﹤0.01% 2954
2025
Q3 		$6.06M Buy
303,785
+48,814
+19% +$877K ﹤0.01% 3208
2025
Q2 		$3.49M Buy
254,971
+4,542
+2% +$43.6K ﹤0.01% 3329
2025
Q1 		$2.77M Sell
250,429
-46,925
-16% -$500K ﹤0.01% 3379
2024
Q4 		$3.17M Buy
297,354
+12,917
+5% +$155K ﹤0.01% 3430
2024
Q3 		$3.61M Buy
284,437
+60,455
+27% +$897K ﹤0.01% 3385
2024
Q2 		$3.76M Buy
223,982
+29,016
+15% +$413K ﹤0.01% 3372
2024
Q1 		$2.92M Buy
194,966
+24,367
+14% +$398K ﹤0.01% 3477
2023
Q4 		$2.56M Buy
170,599
+58,765
+53% +$763K ﹤0.01% 3514
2023
Q3 		$1.57M Buy
111,834
+12,019
+12% +$193K ﹤0.01% 3673
2023
Q2 		$1.03M Buy
+99,815
New +$1.1M ﹤0.01% 3889
2022
Q2 		– Sell
-106,468
Closed -$927K – 4636
2022
Q1 		$927K Sell
106,468
-248
-0.2% -$1.93K ﹤0.01% 4231
2021
Q4 		$1.01M Buy
106,716
+3,518
+3% +$49.6K ﹤0.01% 4261
2021
Q3 		$1.74M Buy
103,198
+6,828
+7% +$108K ﹤0.01% 4102
2021
Q2 		$1.47M Buy
96,370
+3,647
+4% +$65.9K ﹤0.01% 4055
2021
Q1 		$1.81M Buy
92,723
+9,494
+11% +$202K ﹤0.01% 3885
2020
Q4 		$1.5M Buy
83,229
+8,304
+11% +$174K ﹤0.01% 3726
2020
Q3 		$1.45M Sell
74,925
-3,080
-4% -$69.7K ﹤0.01% 3578
2020
Q2 		$2.04M Sell
78,005
-3,220
-4% -$78.7K ﹤0.01% 3426
2020
Q1 		$1.45M Buy
81,225
+636
+0.8% +$17.2K ﹤0.01% 3387
2019
Q4 		$2.69M Sell
80,589
-1,419
-2% -$38.7K ﹤0.01% 3358
2019
Q3 		$1.95M Buy
82,008
+11,709
+17% +$383K ﹤0.01% 3456
2019
Q2 		$2.53M Buy
70,299
+62,778
+835% +$2.31M ﹤0.01% 3404
2019
Q1 		$278K Buy
+7,521
New +$315K ﹤0.01% 3866
2018
Q3 		– Sell
-4,163
Closed -$208K – 4174
2018
Q2 		$208K Buy
+4,163
New +$242K ﹤0.01% 3973

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Vanguard Group's URGN Position: Q4 2025 in Review

Vanguard Group increased its UroGen Pharma (URGN) stake by 45% in Q4 2025, buying an estimated $2.95M and bringing the position to 439,751 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

Vanguard Group first reported a position in URGN in Q2 2018 and has held it in 25 quarters since. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Vanguard Group held 439,751 shares of UroGen Pharma worth $10.3M as of Q4 2025.
  • Vanguard Group bought 135,966 UroGen Pharma shares in Q4 2025, an estimated $2.95M.
  • UroGen Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2954 holding.
  • Vanguard Group first reported a position in UroGen Pharma in Q2 2018 and has held it in 25 quarters since.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.